Investing in Life Sciences Stocks and Companies
TABLE OF CONTENTS
- Human Longevity
- Medical Devices and Imaging
- Brain-Computer Interfaces
- The Drug Discovery Process
- Medical Testing
- Other Life Sciences Themes
- Things We Don’t Understand Very Well
- Interesting Life Sciences Stocks
- Penny Stocks and OTC Stocks
Nowhere will you find more exciting ideas to invest in than “life sciences,” a broad topic that encompasses around 30 different branches of study, each of which could take a lifetime to fully comprehend. As investors, we don’t want to rely on subject matter experts to understand what a company does. If we can’t understand a company’s business, we don’t want to invest in it. We also want to avoid businesses with no traction. Drug development companies with no revenues that are burning through cash trying to bring a drug to market have volatile share prices for a reason. That volatility represents uncertainty. We prefer to stick with businesses that are already selling a product or service which is generating strong revenue growth consistently – like healthcare software-as-a-service offerings. These are businesses that are leveraging life sciences technologies to achieve above-average growth in areas like digital health.
In writing about life sciences over the past seven years, we’ve come across dozens of interesting life sciences companies innovating across the globe such as:
- Zipline has reinvented stitches.
- Kernel is trying to read your brain onto a chip.
- Noom uses AI to help people lose weight.
- Qolty is reinventing how we do medical research.
- Rani Therapeutics is developing robotic pills that perform injections.
- Verily pivoted from smart contact lenses to the digitization of healthcare.
- 908 Devices is miniaturizing mass spectrometers
- Lumicks is building tweezers for molecules.
- Asimov is building tools to program cells.
- Eikon is looking inside cells using fluorescence microscopy
- Pear Therapeutics is using software as therapeutics
- Akili Interactive is using software to treat ADHD
- Sonendo is using acoustic energy for root canals
- Biochimpharm is replacing antibiotics with bacteriophages.
Oftentimes we’ll find groups of startups trying to solve similar problems like creating treatments using the human microbiome or trying to cure hearing loss. Technologies like mobile health, telemedicine, and medical chatbots are democratizing access to healthcare services. Big data is helping us better treat mental health conditions while telepsychiatry now democratizes access to mental health professionals. Apps are now helping us meditate. We’re now able to create bionic limbs, bionic eyes, bionic ears, bionic pancreases, and artificial hearts. Soon, we might be harvesting organs from pigs – something known as xenotransplantation – to help solve the kidney transplant problem. Robots are now performing surgeries, and it won’t be long until robots are doing dental work as well. We’re building labs in the cloud and organs on chips. Optogenetics lets us control cells in living tissues with light. Deep learning algorithms now discover drugs which are then administered using smart pills, smart inhalers, or even wireless drug delivery chips. Patient data is now stored using electronic medical records, data which can then be analyzed by artificial intelligence algorithms to provide things like personalized cancer treatments. When a baby is born, we’re able to store stem cells from cord blood and then use them for stem cell transplants later on in life. These are only the startups we know about, because many life sciences startups choose to operate in stealth mode.
Some of the problems we’re trying to solve are themselves emerging, such as trying to kill superbugs that stem from antibiotic resistance, or developing vaccines for new viruses like “the rona.” (Johnson & Johnson is pouring millions into developing a coronavirus vaccine.)
Many of the problems being worked on involve cures that haven’t been developed yet, something we looked at in our “when will there be a cure” series.
- When Will There Ever be a Cure for Epilepsy?
- When Will There Be a Cure for Parkinson’s Disease?
- When Will There Ever Be a Cure for Hepatitis B?
- When Will There Be a Cure for Creutzfeldt-Jakob Disease?
- When Will There Be a Cure for Lou Gehrig’s Disease?
- When Will There Ever Be a Cure for HPV?
- When Will There Ever be a Cure for Color Blindness?
- When Will There Ever Be a Cure for Autism?
- When Will We Have a Cure for Alcoholism?
- When Will There Ever Be a Cure for Multiple Sclerosis?
- When Will There Be a Cure for Diabetes?
- When Will There Ever Be a Cure for Baldness?
- When Will There Ever Be a Cure for HIV?
- 6 Startups Searching for a Cure for Alzheimer’s
- When Will a Herpes Vaccine be Available?
Examples of innovation in life sciences abound, so we’ve tried to narrow it all down to six areas of focus we’ve been researching for investment opportunities.
- Human Longevity
- Medical Devices
- Brain-Computer Interfaces
- The Drug Discovery Process
- Medical Testing
If you are relatively new to investing, we recommend that you first read our Complete Guide to Buying Stocks for Beginners before continuing. Even advanced degrees in finance don’t cover the many pitfalls out there that can befall first-time investors.
Let’s start by looking at the exciting field of genomics.
Perhaps no field in life sciences shows more promise than that of genomics. Using genetic sequencing machines, scientists are not only able to read the recipes of life, they’re also able to edit them using technologies like gene editing. Whole genome sequencing has now fallen below the $1,000 mark, and some companies now have their sights set on a $50 genome sequencing price point.
Huge databases of DNA data are now being mined for insights, and scientists are even able to reconstruct composite images of criminals from crime scenes using DNA, something referred to as DNA phenotyping.
The field of genomics is exploding as prices plummet, speeds increase, and companies continue to find new use cases. Venture capitalists are pouring money into genomics startups across the globe with China and America being seen as the current leaders in genomics. Companies are not only reading DNA strands but producing them on demand, something referred to as DNA synthesis. In the future, we’ll have a world where everyone is given personalized medicine tailored to their unique genetic makeup. This is why genetic testing is becoming so popular, something we’ll cover extensively later in this piece.
Investing in Genomics Stocks
You can’t talk about genomics without mentioning Illumina, a company that all but dominates the market for machines that perform gene sequencing. We’ve been longtime shareholders in Illumina and added to our position back in 2016 when shares dipped to around $135 a share. As the cost of gene sequencing plummets, even more use cases are opening up for Illumina’s machines leaving them plenty of room for growth. The company is also expanding outside hardware and consumables (which make up ~70% of revenues) into cancer blood testing with their recent acquisition of GRAIL. Regulators weren’t happy with Illumina though, so now they’re required to unwind the purchase. What a mess.
One company trying to disrupt this plan is China’s BGI Genomics which hopes to provide an alternative for Chinese companies that don’t want to use Illumina’s sequencing machines. Oxford Nanopore is a publicly traded U.K company that builds smaller gene-sequencing devices that use a technology called long-read sequencing. Along with Pacific Biosciences, they’re one of two firms doing “true” long-read sequencing (though Illumina recently announced a synthetic method called Infinity). Another publicly traded company to watch in the sequencing space is 10X Genomics which is working on single-cell sequencing. They’re a leader in this space, though revenue growth recently stalled a bit. Also keep an eye on startup GenapSys which finally commercialized their desktop DNA sequencing machine.
Not all genomics stocks are leaders. There are plenty of laggards, like Bionano Genomics (BNGO) which had an IPO back in 2018 and didn’t grow much until only recently. The company sells instruments meant to complement next-generation sequencing machines like those sold by Illumina. When ARK Invest expressed a temporary interest in BNGO, that sent the stock soaring to the moon, something we covered in a piece titled Why is Pacific Biosciences Stock Dropping? Recently, BNGO has shown some signs of life with revenue growth starting to appear. The same holds true for Pacific Biosciences.
In our piece on Designing Proteins to be Molecular Machines, we talked about how the most amazing machines in the world – proteins – are responsible for almost everything that happens in biology. The shapes of proteins help them accomplish their remarkable functions which are completely specified by the sequence of 20 amino acid building blocks used to create proteins. (Nobody knows why nature chose these 20 specific amino acids out of thousands of possible selections.) Chemical forces between these stringy molecules of chained amino acids cause them to fold up into 3D shapes in a fraction of a second, forming proteins.
Perhaps what’s most amazing about proteins is how many unknown proteins there are – proteins that aren’t found in nature – just based on the various combinations 20 amino acid building blocks can form.
Artificial intelligence algorithms are now able to predict protein shapes, something that’s being heralded as one of the biggest scientific breakthroughs in our lifetimes. The study of proteins – proteomics – is expected to explode, and it makes sense to invest in some pure play proteomics stocks. Look no further than our piece on Seven Proteomics Stocks: Finding the Best One. One of the leading proteomics stocks right now, at least by revenues, we covered in a follow up piece titled Quanterix Stock: A Way to Play the Proteomics Boom. Unfortunately, things went pear-shaped for Quanterix in Q2-2022. We also did a deep-dive into a little-known Swedish proteomics stock called Olink. Then there’s SomaLogic which claims to have a significant first-mover advantage in proteomics. In the startup world, Gandeeva Therapeutics is doing some pretty cool stuff with cryogenic electron microscopy and Deepmind’s Alphafold.
Human longevity – also referred to as life extension science – involves extending the human lifespan by rolling back the effects of aging. Technologies like machine learning and genetic sequencing now mean we’re better able to understand the aging process. Google’s Calico has a 10-year R&D collaboration with AbbVie, analyzing millions of anonymous DNA samples in an attempt to better understand the effects of genetics on aging. We’re now able to develop cellular medicines that use live cells to repair the body. (Check out our piece on MaxCyte Stock – Investing in the Future of Cell Therapy.) While technology to analyze cells has been around for a while now, companies like Cytek Biosciences are reinventing techniques like flow cytometry to better study cells. There’s even longevity insurance.
Other companies are trying to increase the human lifespan by lengthening one’s telomeres or by minimizing oxidization which causes aging. Venture capitalists are pouring money into dozens of startups tackling the aging problem in areas like regenerative medicine or young blood transfusions.
From an investor’s perspective, human longevity presents both risks and potential rewards as living another 20 years can have some dire effects on some people’s retirement plans. Of the top longevity companies out there, some are publicly traded – Humacyte (HUMA) makes bioengineered blood vessels – or planning to IPO like regenerative medicine company ACell. Just be aware that some companies out there are selling snake oil. They’re preying on older people who have money and the desire to live longer. Just because someone says they’re selling anti-aging pills doesn’t mean they actually work.
Probably the best way to invest in the potential of regenerative medicine is through pick-and-shovel companies operating cold supply chains, like Cryoport (CYRX) and BioLife Solutions (BLFS).
Medical Devices and Imaging
We’ve talked before about how The Internet of Things promises to connect everything to the cloud with the byproduct being loads of big data. The same holds true in the medical industry where connected medical devices allow doctors to monitor patients’ vital signs from afar. Breath diagnostics devices allow us to more quickly diagnose medical conditions. Ultrasounds can now be performed with smartphones (the biggest player, Butterfly Network, had an IPO which doesn’t look half bad), and ultrasound technology itself is finding many other use cases like finding blood clots that cause strokes and then breaking them up. Newly developed medical devices are used to administer bioelectronic or electroceutical therapies (like neuromodulation) and wearables are helping to treat mental health. We even have AI-powered stethoscopes. Even software is becoming a medical device.
Perhaps some of the biggest advancements are being made in medical imaging where deep learning algorithms are used to interpret medical imagery. Dozens of startups are now developing medical imaging AI algorithms to do everything from measuring breast density to preparing surgeons for surgery.
The increasing sophistication of medical devices and medical imaging algorithms mean that doctors are more easily able to treat patients from afar. Companies like Teladoc (TDOC) make it possible for anyone with $40 to speak with a doctor. For retail investors looking to invest in the telemedicine trend, Teladoc is probably the best telehealth stock to own, but not the only one. Talkspace is set to become a pure-play telehealth stock with a focus on mental telehealth. Babylon Health also went public using a SPAC but their business model has way more risk than we can stomach. There are also many startups working on telehealth using technologies like machine learning to improve upon their offerings.
While telemedicine is about virtual doctor visits, telehealth is about a whole lot more, something we talk about in our pieces on 9 Telehealth Companies Bubbling to the Top and 6 Billion-Dollar Telehealth Companies to Watch. More recently, Teladoc shares have plummeted after a massive impairment charge resulting from their acquisition of Livongo in which we believe they significantly overpaid. A hybrid player in this space is Accolade.
Big Data in Healthcare
As we continue to develop more connected medical devices and generate more medical images, the amount of big data to analyze in healthcare is growing exponentially. Many data analytics businesses are emerging which use this data for predictive analytics or to identify inefficiencies in processes. Oncology is gaining a great deal of momentum as companies like SOPHiA Genetics “push” data analytics solutions to customers’ sites.
The ability to remotely monitor patients means we’re able to treat more people, more effectively. A good example of remote patient care can be found in iRhythm Technologies (IRTC), a company we wrote about in a piece titled Is iRhythm Stock a Buy at Today’s Prices? They’ve built their entire business around a medical device for remote cardiac monitoring. It comes in the form of a wearable that can capture up to two weeks of ECG data while allowing the patient to conduct their life in a perfectly normal fashion. All that data is then fed to “a deep learning model capable of arrhythmia detection at a level comparable to a panel of expert cardiologists for a total of 12 output classes.” Another company working in this space is AliveCor.
Most patient data is now stored electronically instead of being stuffed in some filing cabinet. This means a patient’s data can be shared across healthcare providers allowing for better care. For retail investors, there are a number of publicly traded companies working on electronic health records (EHRs) which are rapidly becoming the norm. Practice Fusion even offers EHRs for free because they know the value is in the data. Companies like Health Catalyst (HCAT) then apply healthcare data analytics to all this big data to create large-scale efficiencies. The leader to watch in this space is IQVIA Holdings (IQV).
A brain-computer interface (BCI) might be the Holy Grail for human advancement. Just imagine being able to increase your brain storage capacity exponentially. And it’s not just about augmenting the human brain. Being able to interface with the human brain means we no longer need to use keyboards or mice. Dozens of startups are working on neurotech applications like neuroprosthetics which can rectify brain damage or neuromodulation which can be used for pain management.
Our brains contain about 2.5 petabytes (2,500,000 gigabytes) of storage, enough to store the entire contents of all US academic research libraries. Stentrodes and neural dust are just some of the methods being used to access this incredible biological data storage mechanism. Biohackers can even do this at home using technologies like OpenBCI. Startups like Kernel are working on Brain-Computer Interface as a Service. Additional BCI use cases can be found in our piece on 9 Neurotechnology Companies Merging Humans and Machines.
The Drug Discovery Process
If you’re not familiar with the drug discovery process, it’s largely inefficient with billions of dollars being spent developing drugs that never actually get approved following clinical testing.
Plenty of companies are working on removing all the inefficiencies from the process. For example, a handful of startups are working on helping patients find clinical trials worldwide which they can then participate in from home, something we covered in our piece on Science 37 Stock for Decentralized Clinical Trials. Some of the biggest advancements being made in drug discovery are the many computational drug discovery startups popping up which use machine learning to optimize the discovery process. Other companies are emulating human organs on chips which can help predict which drugs will fail early on.
When drugs do get approved, some create more problems than they solve. Look no further than America’s addiction to opiates which helps explain the proliferation of startups developing substance abuse apps. Many mental health problems stem from drug abuse, so sometimes cognitive behavioral therapies are a better option than hard drugs. Some of the more severe mental health conditions like schizophrenia still aren’t being treated effectively which means there’s still lots more work to be done.
There is no cure for cancer, there’s only early detection which could make most cancers benign. That’s just one example where advancements in medical testing could prove to save lives and money, something that everyone working in medicine wants to do. Unfortunately, there have been some setbacks for investors, the most notable being the implosion of Theranos. Elizabeth “Crazy Eyes” Holmes was behind the blood-testing company which was fawned over by just about everyone. Now, she’s facing criminal charges while other companies try to fill the Theranos void with their own platforms for blood testing. Some of these come in the form of mobile diagnostics platforms that can be used at the point of care.
Advances in medical testing run the gamut, from AI algorithms that detect Alzheimer’s to blood tests that detect cancer. We’re now able to use next-generation sequencing technologies to identify genomic sequences of pathogens that are present in a patient’s blood or even circulating tumor cells that indicate cancer. We’re even working on building the tricorder from Star Trek.
Cancer Genomics Testing
Many companies are now able to detect the presence of cancer in biofluids like blood or urine. It isn’t just about early detection, it’s also about finding the most effective cancer treatment and monitoring its progress. Traditionally, a doctor would take a piece of a tumor – a biopsy – in order to determine if it is cancerous or benign. Now, many startups are developing liquid biopsies or blood tests that are capable of detecting cancer. One publicly traded company in this space is Guardant Health (GH), an $8 billion precision oncology company that sold over 100,000 cancer blood tests in 2021. They had a hiccup on a key study outcome, but FDA approval is what investors should be focused on.
Another is Personalis (PSNL) which has a patented technology that lets them analyze all 20,000 human genes, though their business model is service-based. ARK Invest likes Freenome, a private company held in their latest fund. You also have Illumina coming into the game with their acquisition of Grail, a company we looked at in a piece titled “Grail – A Pure-Play Stock For Cancer Blood Testing.” Finally, there’s a firm called Biodesix that focuses on lung cancer, and they’ve just filed for an IPO.
Once a type of cancer has been identified, we can then use next-generation sequencing to identify cancer-associated alterations that can be attacked using targeted therapies. Foundation Medicine is a leader in this space with one of the world’s largest cancer genomic databases, holding more than 400,000 genomic profiles. The company had an IPO back in 2013 and got into bed with Roche a few years later. They were finally acquired by Roche in 2018.
Across the pond, we have a few publicly traded companies in this space as well. Angle (AGL.L), a $95 million company which continues to bleed cash while generating minuscule revenues, offers liquid biopsies. Oxford Immunotec (OXFD) is having a bit better luck on the revenue side of things with their blood test for tuberculosis.
ApoCell used to be publicly traded but has since been taken private. There’s also a Japanese firm called Sysmex (6869.T) which is the global market leader in hematology, occupying the number-one share of the worldwide market. They have a subsidiary called Sysmex Inostics which has developed an ultra-sensitive digital PCR technology that is capable of detecting cancer cell DNA directly from blood.
Blood isn’t the only bodily byproduct used to detect cancer. A $13 billion company called Exact Sciences (EXAS) sells a stool DNA test for colorectal cancer, and they’re also developing a liquid biopsy test as well. Exosome Diagnostics – acquired by Bio-Techne – is developing a urine test for prostate cancer. All these samples flying around mean that entire businesses are now being built around the storage and transportation of biological samples.
There are also companies developing cancer therapies that are fine-tuned to certain genomic profiles like personalized chemotherapy. This is where some genetics testing comes in handy.
To say that genetic testing has exploded is an understatement. There are now genetic tests for nearly everything, including genetics tests for pets. In looking at some of these testing use cases, they seem to be borderline gimmicks – like DNA dating or genetic fitness tests. Others provoke a great deal of controversy, like genetic tests for intelligence. There are now DNA apps for nearly everything, but where it all started was with ancestry genetic tests.
Large ancestry testing companies like 23andMe and Ancestry.com quickly realized that the real value to be had was not in selling genetic tests, but collecting genetic data and monetizing it. (23andMe recently had an IPO.) This quickly led to privacy concerns around genetic data. As more and more companies started offering genetic testing services, the big providers started to pivot into genetic healthcare tests for hereditary diseases like cancer or heart disease. Soon, this started to attract the attention of regulatory authorities. Telling someone their dad isn’t their dad isn’t nearly as painful as mistakenly getting a double mastectomy because a genetic test said you were at risk for breast cancer. You’d be surprised to see how many ancestral differences you get when you run the same DNA sample through multiple test providers. (This is why Family Tree DNA offers a central DNA results database where you can upload all your test results.) When it comes to health-related genetics testing, accuracy is paramount.
The evolution of genetics testing is now leading to new business models that try to adapt to the environment. Nebula now offers anonymous DNA testing. CENTOGENE is building the world’s largest repository for genetic information on rare hereditary diseases in the world. We’re learning more about how polygenic risk scores can help predict disease. Being able to interpret genetic data is becoming much easier thanks to technologies like machine learning. Even with all these new technologies, there’s still an important human element to the whole thing. Finding out that you’re at risk for hereditary cancer isn’t all that useful unless someone tells you exactly what that means and what steps you should take if any.
For retail investors, there’s one pure-play genetic testing stock you ought to consider which just expanded into personalized oncology with their acquisition of ArcherDX – Invitae (NVTA). Since we first came across the company seven years ago, they’ve come a long way and managed to put some serious pressure on Myriad Genetics, something we covered in a piece titled Myriad Genetics Stock vs. Invitae Stock. As the markets turn south and capital dries up, we’re concerned that Invitae may need to raise capital at unfavorable terms. In the meantime, Fulgent Genetics is acquiring businesses from cash raised through a pandemic pivot. There’s also CareDx which has a portfolio of diagnostic testing for organ transplants – kidney, heart, and lung.
Other Life Sciences Themes
Some other themes we’ve looked at manifest themselves over time as we notice their prevalence. For example, who knew that diabetes would be such a big industry.
The Diabetes Opportunity
All these people who talk about how “big is beautiful” need to realize that it’s just not. Sure, there are some cultures that glorify obesity because it represents wealth and security. In America, fat asses abound because people drive up to windows to consume two days of calories in one seating – which they then wash down with a diet soda.
The hard truth is that obesity is unhealthy and a contributing factor to a huge global problem – diabetes. We’ve talked before about why there isn’t a cure for diabetes yet. Until there is, we need to treat the more than 100 million U.S. adults who are now living with diabetes or prediabetes.
All kinds of companies are working on diabetes treatments. Dance Biopharm (now Aerami Therapeutics) is working on an inhaled insulin product. Intarcia Therapeutics is working on a potential once-a-year diabetes treatment. But no matter how compelling these products sound, there will be failures, like Cellnovo’s attempt at developing insulin pumps. Kind of hard to compete with Medtronic (MDT), one of the world’s biggest medical device makers, which already has that sorted with a digital form of an artificial pancreas though others have too. (Full disclosure: we’re long-time shareholders in MDT for dividend growth reasons.) One company that’s presently challenging Medtronic in the area of Constant Glucose Monitoring (CGM) sensors is Dexcom (DXCM), a $41 billion diabetes pure-play stock that’s seeing some explosive growth in revenues from CGM. There’s still plenty of growth left for this firm which has 80% of revenues coming from consumables, just maybe not as much as they claim. Their competitor, Senseonics, is a firm we’re avoiding. Also in the diabetes space is Oramed and their oral insulin which should be avoided like the plague.
Non-Invasive Prenatal Testing (NIPT)
Another theme we looked at for a bit was non- invasive prenatal testing (NIPT) which is pretty much what it says on the tin. It’s a test that makes sure your little bundle of joy doesn’t pop out with two heads, or be afflicted by any malady that would interfere with the perfect life you’ve planned for it. Plenty of companies are dabbling in this space, like Ariosa Diagnostics which was acquired by Roche since we last looked at them. Other publicly traded stocks in this space include Natera (NTRA) and Premaitha Health (BQB1.SG) which now goes under the name Yourgene.
We stopped looking at NIPT because we believed the NIPT growth story might be ending. We also didn’t find the topic to be that interesting frankly – unless of course they come out with a NIPT for intelligence which we’d probably invest in.
Stem cells are kind of like a foundation cell that various types of other cells get built on like muscle cells or brain cells. These are useful for applications like regenerating body parts or figuring out what makes cancer cells replicate. One company we looked at, Cellular Dynamics, was in the business of producing stem cells. They’ve since been acquired by Fujifilm Holdings. Another company we looked at was Fate Therapeutics (FATE) which uses renewable master induced pluripotent stem cell (iPSC) lines to produce cellular immunotherapies. We have no idea what that actually means, which is why we’re not investors in the company. We only like to invest in businesses we can easily understand, which is also why we’re avoiding Cellect Biotechnology Stock (APOP).
Things We Don’t Understand Very Well
Over the years of developing our life sciences topics, we encountered quite a few companies that we just didn’t fully understand. Roivant Sciences was one of them. So were the “nant” companies coming from the brain of Dr. Soon-Shiong, one of the world’s most successful biotech investors. It’s very difficult to understand some of these businesses without having a medical background, and if you need eight years of training to understand what a company does, it’s probably too complex for retail investors. We’ve given up on trying to figure out how NantHealth will revolutionize the U.S. healthcare system, or what NantKwest does, and instead stick to companies with business models anyone can understand. Another area of life sciences we’ve looked into before but decided not to follow is RNAi therapeutics.
Another area we looked at briefly was RNAi therapeutics and publicly-traded RNAi companies like Benitec, Dicerna Pharmaceuticals, or Moderna which has soared after going public due to their work on a coronavirus vaccine. To this day, we still don’t feel like we sufficiently understand what many of these companies do which means we’re not able to properly explain them to our readers. Instead of spending hours trying to understand how microRNA relates to RNAi, we’re staying away from drug development companies entirely (AI drug developers being the possible exception here). Even if a company has the greatest drug development platform in the world, there’s always a risk they’ll fail given all the pitfalls of drug development we discussed earlier. The exception to that rule might be the drug development arm of Johnson & Johnson, a company we hold as part of our dividend growth investing strategy.
Fields like cancer immunotherapy, cancer stem cell research, or epigenetics may have loads of promise, but most of these investments are just too complex for your average Joe investor to understand without having an interpreter. Let’s talk about some stocks that you don’t need an interpreter to understand.
Interesting Life Sciences Stocks
Some of you working in finance may not be able to trade stocks, so maybe you’ll want to check out the First Trust Nasdaq Lux Digital Health Solutions ETF. For the rest of you, there are numerous life sciences stocks that you can peruse, a handful of which we’ve invested in ourselves.
Given the breadth of technologies to be found under life sciences, we often take fleeting looks at companies that are doing cool things without necessarily doing any deep-dives or follow-ups. These one-offs are oftentimes stocks or planned IPOs we come across that we think our readers might find interesting. Some of these names include:
- A company called Eyenovia (EYEN) is trying to reinvent the eyedropper, but all they’ve done since their IPO is just lose a bunch of money.
- Inspire Medical Systems (INSP) was spun out of Medtronic to develop an alternative treatment for sleep apnea. Revenue growth has been strong for this $2.5 billion company.
- DermTech (DMTK) has developed a scalpel-free test for skin cancer and went public in 2019. Revenues are appearing slowly while cash is burning quickly.
- CareDX (CDNA) sells a heart transplant rejection test that’s used by over 90% of U.S. transplant centers. After some initial concerns, they’re now showing very strong revenue growth and shrinking losses.
- Finally, in the femtech niche, we have Agile Therapeutics (AGRX), a company that’s developed a once-a-week hormonal contraceptive patch that is on the cusp of being sold.
One thing all these stocks have in common is that they’re traded on major exchanges unlike penny stocks which you should avoid like the plague.
Penny Stocks and OTC Stocks
We never skip a chance to warn investors about the dangers to be found when dabbling in penny stocks (also called over-the-counter (OTC) stocks). Here are just some of the OTC companies we’ve written about.
- Cellceutix – Lost -74% of its value since our piece and now goes under the name Innovation Pharmaceuticals (IPX).
- Propanc – Lost -99.5% of its value after we cautioned investors about this piece of garbage.
- PharmaCyte Biotech – This gem lost -81% of its value since we warned investors about it.
- Regen BioPharma – After losing -99.9% of its value since their IPO, this steaming pile of shite is still actually being traded, and the results are best portrayed by the below chart:
Investing in any of these companies would have proved to be a total disaster. Of course, there are always some exceptions, but why try to walk through landmines to find them? Do not speculate on penny stocks, no matter how compelling their story is.
Oftentimes we’ll come across micro-cap stocks on foreign exchanges which we’ll write about. More often than not, these companies will end up going nowhere fast. Kiwi company Adherium (ADR.AX) was supposed to bring us intelligent inhalers. While investors continue to wait, their share price continues to plummet. We warned investors that Canadian firm Biomark Diagnostics (BUX:CN) might not have what it takes to bring cancer blood tests to market, and the company still appears to be going nowhere fast. London’s Tissue Regenix (LSW1.BE) was working on some exciting new skin scaffolds, but you would have lost -90% of your investment waiting for them to finally start achieving some traction. Even though revenues are picking up and losses are trending in the right direction, shares continue their long downward slide. It’s best not to try and catch a falling knife.
Some readers may wonder why we haven’t touched on one of the most exciting technology there is – synthetic biology. That’s because we’ve dedicated an entire page to synthetic biology, our Guide to Investing in Synthetic Biology. The same holds true for gene editing, something we covered in our Guide to Investing in Gene Editing Stocks. We happen to classify gene editing and synthetic biology under our nanotechnology category, so you may want to go read our Guide to Investing in Nanotechnology Stocks and Companies next. Because life sciences is such a broad category, you’ll find it peppered throughout all the twelve categories of disruptive technologies we cover here at Nanalyze. For example, machine learning algorithms are now helping us understand extremely complex things such as the human microbiome.
Sure, you can cure your STDs without going to a doctor, but developing something as simple as a universal flu vaccine is still out of reach. While plenty of progress is being made in life sciences, there are still plenty of diseases we can’t cure and problems we can’t solve, like the newly emerged pandemic which is having a curious effect on the equities market. It’s safe to say that investors will continue to reap rewards by investing in life sciences companies for decades to come.
Tech investing is extremely risky. Minimize your risk with our stock research, investment tools, and portfolios, and find out which tech stocks you should avoid. Become a Nanalyze Premium member and find out today!